Transdel Pharmaceuticals Advances Lead Topical Pain Drug Into Phase 3 Program Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) announced that based on the U.S. Food and Drug Administration's ("FDA") review of its Phase 3 submission the Company can initiate its Phase 3 clinical program for its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID"), Ketotransdel(TM). Transdel Pharmaceuticals is a specialty pharmaceutical company pursuing the development and commercialization of non-invasive topically administered medications.
Source: www.medicalnewstoday.com
# posted by Network @ 3:00 AM
